

REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Date: May 15, 2024

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir,

Sub: Presentation to the Analysts/Investors

We refer to the audited financial results for the fourth quarter and financial year ended on March 31, 2024, submitted to you today i.e., on May 15, 2024. We are now enclosing the presentation in this regard to the Analysts/Investors.

This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**





**Transforming Healthcare
through Innovation and Sustainability**

Granules India Limited

Earnings Presentation

Q4 & Full Year FY24



15th May 2024

Safe Harbour Statement

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Key Business Updates For Q4 FY 24

Performance

- Strong uptick in gross margin for the quarter as well as for the full year FY 24.
- Continued growth in formulations share in the business, driven by CNS/ ADHD portfolio and other new products.
- Growing contribution from new products in the product mix
- Decline in the Para API sales due to higher customer inventory and price erosion. Partly offset by growth in FD sales

Capacity and Capability building

- Granules Life Sciences (GLS), with planned FD capacity of 8 Bn dosage, successfully commenced operations in March 24. The facility to achieve 2.5 Bn dosage run rate by March 25
- Continued prioritization and investment in R&D, towards building our product development capabilities and product pipeline in identified segments

Product Approvals for Q4 FY 24


- Metoprolol Succinate PR Tablets 25 / 50 / 100 & 200 mg (EU DCP)ANDA
- Ibuprofen Tablets 200/400 mg (OTC) (SA)

Business Strategy Update

Strategy In Action: A Breakout Year for FD portfolio and Product Diversification


Moving Up the Value Chain

Revenue Share By Business Segment




Product Diversification

Revenue Share By Product Segment



Strategy In Action: Strengthening Business in North America



Unique Manufacturing Platform of Optimizing “**Make in India**” (GIL) and “**Make in America**” (GPI , GPAK)


Market leadership in CNS/ADHD (GPI operations), adding to the leadership position in large volume molecules

GPI Market leadership: 7 products are ranked #1 (MAT March 24), contributing 70% to the GPI’s revenue.


Prioritizing OTC business through GCH and GPAK : Growing OTC business through partnership with Brand owners and leading Retailers in the US. 2 products have the market leadership.

Business Growth to be driven by primarily new launches, both in Rx and OTC, supplemented by BD in new dosage forms

Strategy In Action: Portfolio Expansion



Strategy In Action: Prioritizing Investment in Building R&D Capability and Product Pipeline



Integrated Product Development

Genome Valley – MN Park

R&D facility for Integrated Product Development

- ~170 scientists across API & FD R&D
- Fast tracking product development through seamless coordination & shared analytical resource

Controlled Substances

- ### Pragathi Nagar R&D
- CoE for CII API Development
 - Select KSMs


- ### GPI R&D
- CII Finished Dosage
 - Complex technologies FD

New Technologies


- ### Bio Lab at Pragathi Nagar
- Enzyme & Fermentation

- ### Pune R&D
- New technologies
 - KSM & Backward Integration

Strategy In Action: Building & Sustaining Key Product Leadership



Strategy In Action: Expanding Reach Through Commercial Excellence



Replicate commercial success of North America in other key markets
Strengthening Teams | Building Commercial Excellence Processes

- Revamped and augmented **Commercial leadership team**
- **Formulation Driven Growth in Europe** through key partnerships and Dossier Sales/ BD Deals on existing and New Products
- **Extension of the Commercial portfolio and new products**
- **Customer focus:** New Initiatives focus on customer service excellence

Sustainability at Granules : Green Molecule Platform, beginning with our core products – Paracetamol & Metformin

GRANULES
CZRO

Commitment towards Net Zero

Medicine with *near Net Zero Carbon footprint*

24/7
Carbon-free energy

Green molecules

Such as Hydrogen (H₂), Ammonia (NH₃), Nitric acid (HNO₃) and Methanol (CH₃OH)

Built-in circularity

Develop and Promote State-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh	Supply of Carbon Free Green Energy and Green Molecules Solutions	To build a green field facility for large scale manufacturing of KSMs, Intermediates, APIs and fermentation-based products



CZRO Update

Granules CZRO has initiated a pilot DCDA plant in Visakhapatnam. The pilot plant has commenced operations in the month of March'24.

Quarterly Performance

Q4FY24: Y-o-Y performance highlights – P&L

(In ₹ Mn)

	Q4 FY24	Q4 FY23	Y-o-Y Gr%
Revenue	11,758	11,955	(2)% ↓
Value Added	7,062	5,720	23% ↑
Value Added %	60.1%	47.8%	
EBITDA	2,557	2,281	12% ↑
EBITDA %	21.7%	19.1%	
PAT	1,296	1,196	8% ↑
PAT %	11.0%	10.0%	

Y-o-Y performance

Formulations growth including GPI manufactured products offset by decline in Para API sales volume and price erosion

Achieved a higher value-added percentage compared to Q4-FY23, attributed to a higher FD sales and lower raw material cost

Improved Value-Added Percentage (VA%) led to a better EBITDA percentage in Q4 FY24, despite increase in R&D spend for building R&D pipeline

Increase in interest rate impacted PAT of Q4 FY24

Q4FY24: Q-o-Q performance highlights – P&L

(In ₹ Mn)

	Q4 FY24	Q3 FY24	Q-o-Q Gr%
Revenue	11,758	11,556	2% ↑
Value Added	7,062	6,582	7% ↑
<i>Value Added %</i>	60.1%	57.0%	
EBITDA	2,557	2,504	2% ↑
<i>EBITDA %</i>	21.7%	21.7%	
PAT	1,296	1,257	3% ↑
<i>PAT %</i>	11.0%	10.9%	

Q-o-Q performance

Inline with our strategic focus, continued FD sales growth including GPI manufactured products offset by decline in Para API sales volume and price erosion


Achieved a higher value-added percentage compared to Q3-FY24, attributed to a higher FD sales

Increased R&D spend for building R&D pipeline

Q4FY24 Revenue split by Segments and Market


(In ₹ Mn)

Division wise share



	Q4 FY23	Q4 FY24	Y-o-Y Gr%
API	3,664	1,633	(55%)
PFI	2,174	1,482	(32%)
FD	6,117	8,642	41%

Region wise share




	Q4 FY23	Q4 FY24	Y-o-Y Gr%
North America	6,962	8,260	19%
Europe	2,871	2,013	(30%)
LATAM	720	539	(25%)
India	680	378	(44%)
ROW	722	567	(21%)


Last 5 quarters historical performance – Sales and profitability

(In ₹ Mn)


Sales




VA and VA %



EBITDA and EBITDA %



PAT and PAT %




FY24 Performance is affected by cyber incident faced in Q1FY24


Last 5 quarters historical performance – Cashflow and Ratios

(In ₹ Mn)


ROCE%




Asset turns




Net debt and Net debt/EBITDA




Working Capital days



Operating Cash flow



Capex



FY24 Performance is affected by cyber incident faced in Q1FY24

Yearly Performance

FY24: Y-o-Y performance highlights – P&L

(In ₹ Mn)

	FY24	FY23	Y-o-Y Gr%	Y-o-Y performance
Revenue	45,064	45,119	0%	Despite a cyber incident and decline in Para API Volume and price erosion, transformative focus into formulations including GPI manufactured products enabled the company to sustain the similar turnover YoY
Value Added	24,851	22,046	13% ↑	Achieved a higher value-added percentage compared to FY23, attributed to a higher FD sales and lower raw material cost
Value Added %	55.1%	48.9%		
EBITDA	8,560	9,138	-6% ↓	The decrease in EBITDA margin compared to last year is primarily due to increase in R&D spend for R&D pipeline. There is growth in EBITDA before R&D spend.
EBITDA %	19.0%	20.3%		
PAT	4,053	5,166	-22% ↓	Increase in interest rate has impacted the PAT margin significantly
PAT %	9.0%	11.4%		

FY24: Y-o-Y performance highlights – Cashflow and Ratios

(In ₹ Mn)

	FY23	FY24
ROCE%	21.2%	16.5%

Decrease in EBIT, decrease in asset turnover and increase in CCC days has led to a decline in ROCE

ROCE = Annualised EBIT / Average capital employed
 Capital employed = Equity + Total Borrowings + LT liabilities - Cash

	FY23	FY24
CCC	132	161

New launches and Red sea issues impacted both inventory days and overall CCC days

CCC = DIO + DSO - DPO

DIO and DPO are calculated using Material Cost consumed and DSO is calculated using Sales

	FY23	FY24
Fixed asset turn	2.06	1.77

Affected due to sales price erosion and Investments in Granules life science and CZRO

Fixed asset turn = Annualised Sales / Average Tangible Gross block

	FY23	FY24
Operating Cashflow	7,387	4,394

Affected due to a reduction in EBITDA and an increase in CCC days

	FY23	FY24
Net debt/ EBITDA	0.84x	0.98x

Net debt increase is maintained

Net debt = Gross debt – Cash and cash equivalents


	FY23	FY24
Capex	4,105	3,788

FY24 Capex includes investment towards Granules life sciences (1,560 Mn) and CZRO (565 Mn)

FY24 Revenue split by Segments


(In ₹ Mn)

Division wise share



	FY23	FY24	Y-o-Y Gr%
API	13,414	9,866	(26%)
PFI	9,021	6,107	(32%)
FD	22,684	29,090	28%

Region wise share




	FY23	FY24	Y-o-Y Gr%
North America	25,880	29,866	15%
Europe	10,210	8,826	(14%)
LATAM	3,443	2,035	(41%)
India	2,895	2,256	(22%)
ROW	2,691	2,080	(23%)

Last 5 years historical performance – Sales and profitability


(In ₹ Mn)




Sales: 5yr CAGR: 15%




VA and VA%: 5yr CAGR: 19%



EBITDA and EBITDA%: 5yr CAGR: 17%



PAT and PAT%: 5yr CAGR: 11%




FY24 Performance is affected by cyber incident and Para API market and price erosion


Last 5 years historical performance – Cashflow and Ratios

(In ₹ Mn)


ROCE%




Asset turns




Net debt and Net debt/EBITDA




Cash to Cash cycle



Operating Cash flow



Capex




FY24 Performance is affected by cyber incident and Para API market and price erosion

ANDA/Dossier filing status

Filing Status	GPI IP	GRANULES					Total
	USA	USA	Europe	Canada	Others (SA, Belarus, Israel & India)	UK	
Approved	26	36	9	6	4	2	83
Tentatively Approved	1	1	-	-	-	-	2
Filed	5	8	1	-	6	-	20
Total Products	32	45	10	6	10	2	105

ANDA/Dossier filed - Therapeutic area wise



Granules at a Glance

Granules Purpose, Vision & Values

Purpose

Healing lives
responsibly
through pioneering
green science

Vision

To establish ourselves as a world leader in green chemical and pharmaceutical industry by harnessing cutting-edge technologies to enhance quality of life.

Values

- 1 Challenging Limits
- 2 Futuristic Thinking
- 3 Empowering Employees
- 4 Customer Driven
- 5 Quality Everywhere
- 6 Environmental Stewardship

An Illustrious Journey Spanning Four Decades

Building A World Class, Vertically Integrated Pharmaceutical Manufacturing Platform

From being a paracetamol API manufacturing facility to a multi-faceted global pharmaceutical company, we have consistently achieved manufacturing success, set new standards of quality and expanded our presence across the world.



Triton Laboratories was formed to produce Paracetamol API at our Bonthapally facility in Hyderabad



A new large volume PFI facility in Gagillapur and a wholly owned subsidiary - Granules USA for marketing in the US



Acquired Auctus Pharma - An API Manufacturing Facility with regulatory approvals



Laid foundation for Oncology OSD Plant in Visakhapatnam



GPAK is a 79,000 sq. ft. packaging facility with 4 packaging suites & WH facility

1984

1990

2003

2008

2013

2014

2016

2021

2023

Triton opened its second manufacturing facility at Jeedimetla to produce multiple APIs



Entry into the Finished Dosage segment



Sets up a wholly owned subsidiary in the US; Granules Pharmaceutical to focus on formulation R&D to forward integrate its APIs



Largest single manufacturing site for Multi-Unit Pellet system facility



Manufacturing Network & Capacity

Bonthapally



API: 34,560 TPA

Jeedimetla



**API: 4,800 TPA
PFI: 1,440 TPA**

Gagillapur



**FD: 26.8 Bn
PFI: 23,200 TPA**

Virginia, USA



FD: 1.5 Bn

GPAK, USA



**2 OTC lines
1 Rx line**

Bonthapally II



**API (Intermediate):
61.5 KL PA**

Vizag (Unit 4)



API: 380 KL PA

Vizag (Unit 5)



**API: 15 KL PA
FD: 1.1 Bn**

Genome Valley



**FD: 8 Bn dosage (Upcoming)
(Phase 1: 2.5 Bn dosage by end of FY 25)**

Sustainability at Granules : Pioneering Innovation for Complete Supply Chain Decarbonization of Pharmaceuticals

Net Zero by **2050**

The Granules Commitment

GRANULES **CZRO**

Building our flagship green pharmaceutical plant*
*(At Kakinada, AP, India)

C Score

Received for Climate change in our first CDP disclosure

BB

Our Inaugural MSCI ESG Rating

Silver Rating*

*Achieved by Unit-1 Bonthapally

27.8 % ↓

Scope1 and Scope2 Intensity*

*Over last year

22.8 % ↓

Scope1 and Scope2 Absolute Reduction*

*Over last year

SCIENCE BASED TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

Committed to set a science-based target through the Science Based Targets initiative (SBTi)

WE SUPPORT

UN GLOBAL COMPACT

47.7 % 🌱

Share of Renewable Energy of Electricity Consumed Including PPA & I-RECS *

88.1 % ♻️

Haz.Waste generated sent for Co-processing

ESG / Sustainability Disclosure

1. Baseline & Estimation : Granules Carbon footprint

- Scope 1 & 2 emissions for FY 24 : 86,854 tCo2 eq (22.8% reduction Y-0-Y).
 - 47.2% RE share in Purchased electricity using PPAs & I-RECs
- Scope 3: comprehensive assessment completed for FY 23
 - Total Emission : 624,675 tCo2 eq for FY 23; ongoing estimation for FY 24

2. **Product Carbon Footprint** : completed for 5 products- Paracetamol, Metformin, Potassium chloride, Metoprolol, venlafaxine

3. **Net Zero Roadmap & Decarbonization Action Plan** : The roadmap is finalized with action plans for Scope 1, Scope 2 and Scope 3

- Scope 1** : Actions initiated : Alternate fuel for boilers such as biofuel or bio briquettes. Efficiency improved measures identified and being implemented
- Scope 2**: Adoption of RECs, initiated additional PPA discussions, and identified efficiency improvement measures for action
- Scope 3**: Vendor engagement and Supplier sustainability program finalized. Specific procurement (e.g., switching vendor) actions identified

4. Governance, Target Setting & KPIs

- ESG Governance structure and Sustainability review mechanism incorporated
- Long term and Mid term Climate targets finalized, aligned with **SBTi 1.5 degrees guidelines and Net Zero 2020 pathway**
- Sustainability linked targets incorporated in Annual KPIs for the corporate, and individual functional KPIs


5. **Recognition & Awards** : Granules received Economic times (ET) Sustainability award in Jan 24.

6. **Initiated discussions and engagement with our key customers** in Europe and North America on our decarbonization commitment, roadmap and action plan

Our Carbon Footprint : Scope 1 & Scope 2 : FY 23 & FY 24

#	UOM	FY 22-23	FY 23-24
Scope 1 Emission	MT Co2e	56,265	55,121
Scope 2 Emission			
Scope 2- Location Based	MT Co2e	62,432	60,104
Scope 2- Market Based	MT Co2e	56,306	31,733
Total Scope 1 & Scope 2- Location Based			
	MT Co2e	1,18,697	1,15,225
Total Scope 1 & Scope 2- Market Based			
	MT Co2e	1,12,571	86,854

Our Carbon Footprint : Scope 3 assessment for FY 23 (624,675 tCo2 eq.)




Scope 3 assessment for FY 24 under finalization

Sustainability at Granules : Adopting Green Chemistry and Sustainable Formulation manufacturing


Adopting Green Chemistry Principles

Innovation & Sustainability built into product



Enzyme & Bio Transformation

- Mild reaction conditions,
- Greater selectivity,
- Eco friendly substitute to metallo-catalysis



Flow Technology & Continuous Manufacturing

- Faster and efficient reactions
- Lower footprint
- Safer Operations

Sustainable Formulations Manufacturing

Plant based Excipients

Biodegradable Plastic

Solvent / Polymer free Pharmaceuticals

Energy Capture

Reducing Water Consumption

Green Score in R&D Development

Implementation of Green card and Eco scale initiatives from the early stages of development

Green Chemistry Matrix

Atom Economy

Atom efficiency

E-factor

Eco-Scale for process efficiency

6 parameters & 38 sub-parameters at every stage of the reaction

Yield

Safety

Effluent

Input/ RM Cost

Operations Parameters

Infrastructure considerations

Social Impact Initiative : Pharma Pathshala @ Swarna Bharat Trust

Granules initiative to train a rural workforce through the Swarna Bharat Trust

Vocational education & technical skills in pharmaceutical operations to High School youth to ensure employment in any pharmaceutical manufacturing company.

GRANULES INDIA IS ENGAGED IN:

- Setting up of the infrastructure along with classrooms, laboratories, etc.
- Developing the course content
- Training the trainers
- Providing faculty
- Providing industrial internship for the students
- Assessing & certifying the students on completion of the course

COURSE CONTENTS:

Enhancing Technical Skills

CGMP

Unit Operations

Communication

Analytical Thinking

Basics of pharmaceuticals

Pharma Analysis

Enhancing Soft Skills

Time Management

Decision Making





For investor relation – Granules IR desk

Email: investorrelations@granulesindia.com

www.granulesindia.com



Ms. Payal Dave

payal.dave@linkintime.co.in

Mr. Irfan Raeen

+91 97737 78669

Irfan.raeen@linkintime.co.in

www.orientcap.com

thank you!



BSE 532482

NSE GRANULES

Bloomberg GRAN:IN

REUTERS GRAN:NS

Corporate address:

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081

CIN: L24110TG1991PLC012471

Voice: +91 40 69043600

www.granulesindia.com